CytomX Therapeutics (NASDAQ:CTMX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. CytomX Therapeutics had a negative net margin of 158.05% and a negative return on equity of 77.05%. The firm had revenue of $10.71 million during the quarter, compared to the consensus estimate of $23.58 million.
Shares of NASDAQ CTMX traded down $0.20 during mid-day trading on Friday, reaching $5.95. 538,700 shares of the company were exchanged, compared to its average volume of 437,329. The company’s 50 day moving average price is $7.14 and its 200 day moving average price is $9.47. CytomX Therapeutics has a 52 week low of $5.28 and a 52 week high of $19.75. The stock has a market capitalization of $281.99 million, a PE ratio of -2.93 and a beta of 0.64. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 0.26.
Several research analysts have commented on CTMX shares. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. BidaskClub downgraded shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Nomura reissued a “buy” rating and issued a $22.00 price target on shares of CytomX Therapeutics in a report on Sunday, August 11th. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, August 7th. Finally, Mizuho reissued a “buy” rating and issued a $16.00 price target on shares of CytomX Therapeutics in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $20.14.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: Why is Cost of Capital Important?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.